Simple bathroom habit may cut infection risk after kidney transplant
NCT ID NCT05711446
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a simple technique called double voiding—urinating twice in one bathroom visit—can reduce urinary tract infections (UTIs) in kidney transplant recipients. UTIs are common after transplant and can lead to serious complications. The trial will compare double voiding to usual voiding in 438 adult kidney transplant patients. If effective, this low-cost, no-risk habit could improve outcomes for transplant recipients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Double voiding (a behavioral technique of urinating twice in one bathroom visit)
- What this could lead to
- If it works, this simple technique could reduce UTIs, hospital stays, and complications after kidney transplant.
- What could go wrong
- This is a behavioral intervention with low risk, but it may not significantly reduce infections. The trial is still recruiting, so results are pending.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 438 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2023
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All adult kidney transplant recipients who undergo routine follow-up at the New York Presbyterian - Weill Cornell Medicine (NYP-WCM) Transplant Clinic. Exclusion Criteria: * Kidney transplant recipients who are discharged after a transplant with an indwelling catheter (Foley)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Kidney transplant; complications are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Weill Cornell Medical College / NY Presbyterian
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chilling donors: can cooling Brain-Dead organ donors make kidney transplants work better?
- Gut bacteria transplant tested against Antibiotic-Resistant urinary infections
- Why do some complicated UTIs resist treatment? massive study aims to find out
- Could removing catheters sooner after kidney transplant cut infections?
- Can a vaccine shield transplant patients from shingles?
- Can a single drug dose forecast transplant kidney health?